The clinical application of intralesional administration of the SD101 TLR9 agonist has proven efficacy in untreated indolent lymphomas, in combination with local radiotherapy, achieving in some patients a reduction in tumor size not only of the treated lesion but also in their untreated sites [28]. Here, TLR9 is linked to lymphoma.